[go: up one dir, main page]

NO930243D0 - Adoptiv immunoterapi med interleukin-7 - Google Patents

Adoptiv immunoterapi med interleukin-7

Info

Publication number
NO930243D0
NO930243D0 NO930243A NO930243A NO930243D0 NO 930243 D0 NO930243 D0 NO 930243D0 NO 930243 A NO930243 A NO 930243A NO 930243 A NO930243 A NO 930243A NO 930243 D0 NO930243 D0 NO 930243D0
Authority
NO
Norway
Prior art keywords
lymphoid cells
interleukin
individual
specific antigen
adoptive immunotherapy
Prior art date
Application number
NO930243A
Other languages
English (en)
Norwegian (no)
Other versions
NO930243L (no
Inventor
David H Lynch
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO930243D0 publication Critical patent/NO930243D0/no
Publication of NO930243L publication Critical patent/NO930243L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
NO93930243A 1990-07-26 1993-01-25 Adoptiv immunoterapi med interleukin-7 NO930243L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/559,001 US5229115A (en) 1990-07-26 1990-07-26 Adoptive immunotherapy with interleukin-7
PCT/US1991/004919 WO1992001459A1 (fr) 1990-07-26 1991-07-12 Immunotherapie adoptive utilisant l'interleukine-7

Publications (2)

Publication Number Publication Date
NO930243D0 true NO930243D0 (no) 1993-01-25
NO930243L NO930243L (no) 1993-01-25

Family

ID=24231881

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930243A NO930243L (no) 1990-07-26 1993-01-25 Adoptiv immunoterapi med interleukin-7

Country Status (16)

Country Link
US (1) US5229115A (fr)
EP (1) EP0540599B1 (fr)
JP (1) JP3825467B2 (fr)
AT (1) ATE161180T1 (fr)
AU (1) AU646881B2 (fr)
CA (1) CA2087525C (fr)
DE (1) DE69128476T2 (fr)
DK (1) DK0540599T3 (fr)
ES (1) ES2112860T3 (fr)
FI (1) FI105045B (fr)
GR (1) GR3026358T3 (fr)
IE (1) IE912486A1 (fr)
IL (1) IL98957A (fr)
NO (1) NO930243L (fr)
NZ (1) NZ239113A (fr)
WO (1) WO1992001459A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
CA2157379A1 (fr) * 1993-03-02 1994-09-15 David S. Terman Methode pour le traitement du cancer
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
BR9712988A (pt) * 1996-10-11 2000-10-24 Univ California Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
CA2321161C (fr) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions renfermant un agent de liaison du recepteur ox-40 ou un acide nucleique codant pour ledit recepteur 0x-40 et techniques favorisant une reponse immunitaire specifique a un antigene
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2016930B1 (fr) 2001-02-20 2014-10-15 Janssen Pharmaceuticals, Inc. Suspension des cellules CD8 pour l'utilisation dans le traitement des mélanomes
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
JP2005509434A (ja) * 2001-11-22 2005-04-14 メディジーンズ インターロイキン−２遺伝子が導入されたリンフォカイン活性キラー細胞
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
WO2007120673A2 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogènes et leurs méthodes d'utilisation
MX2009003362A (es) 2006-09-28 2009-06-08 Schering Corp Uso de interleucina-10 pegilada para tratamiento de cancer.
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗
WO2012123269A1 (fr) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Compositions immunigènes et procédés pour leur utilisation
EP2505640A1 (fr) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Compositions de vaccins pour maladies provoquées par le birnavirus
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
SI2945647T1 (sl) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2961416B1 (fr) 2013-03-01 2019-11-13 The United States of America, as represented by The Secretary, Department of Health and Human Services Procédés de production de populations enrichies de lymphocytes t réactifs à une tumeur à partir de sang périphérique
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
CA2947290A1 (fr) 2014-05-05 2015-11-12 Lycera Corporation Sulfonamide de tetrahydroquinoline et composes apparentes destines a servir d'agonistes de rory et pour le traitement de maladies
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016064817A1 (fr) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP4606387A3 (fr) 2015-08-25 2025-11-19 Armo Biosciences, Inc. Procédés d'utilisation d'interleukine-10 pour le traitement de maladies et de troubles
EP3551629B1 (fr) 2016-12-08 2023-11-15 Lixte Biotechnology, Inc. Oxabicycloheptanes pour la modulation de la réponse immunitaire
WO2018162450A1 (fr) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada Nouvelles compositions immunostimulatrices comprenant une entité protéine de liaison à l'arn inductible à froid (cirp)-antigène pour l'activation des cellules dendritiques
US20210379106A1 (en) * 2018-06-14 2021-12-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU3183089A (en) * 1988-02-11 1989-09-06 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
JPH05509093A (ja) 1993-12-16
GR3026358T3 (en) 1998-06-30
US5229115A (en) 1993-07-20
JP3825467B2 (ja) 2006-09-27
WO1992001459A1 (fr) 1992-02-06
IL98957A0 (en) 1992-07-15
DK0540599T3 (da) 1998-08-24
CA2087525A1 (fr) 1992-01-27
FI930206A0 (fi) 1993-01-19
NZ239113A (en) 1997-07-27
AU646881B2 (en) 1994-03-10
IE912486A1 (en) 1992-01-29
CA2087525C (fr) 2006-05-30
AU8287291A (en) 1992-02-18
IL98957A (en) 2000-11-21
ATE161180T1 (de) 1998-01-15
ES2112860T3 (es) 1998-04-16
DE69128476D1 (de) 1998-01-29
FI105045B (fi) 2000-05-31
EP0540599A1 (fr) 1993-05-12
DE69128476T2 (de) 1998-07-23
EP0540599B1 (fr) 1997-12-17
FI930206L (fi) 1993-01-19
NO930243L (no) 1993-01-25

Similar Documents

Publication Publication Date Title
DK0540599T3 (da) Adoptiv immunterapi med interleukin-7
FI953731A0 (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
ATE296875T1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE195875T1 (de) Spezifische modulationen des immunsystems
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
DE69533941D1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
DE69028320D1 (de) Illudin-analoge, verwendet als antitumormittel
DK372780A (da) Fremgangsmaade til propagering af humant hepatitis a virus
ATE15693T1 (de) Zellkultur-verfahren.
Rees et al. Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test
ATE87215T1 (de) Verfahren zum erhalten von immunregulierenden faktoren mittels saeugetierimmunisierung.
NO922422L (no) Matrise med adherent bundede celler, samt fremgangsmaate ved fremstilling av virus/virusantigener
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
Miller et al. Immunological studies in murine osteosarcoma. Immunogenicity, growth kinetics, and immunotherapy
PT72015B (en) Process for preparing "invitro" cultures of hepatitis b virus
Law et al. A unique tumor rejection antigen from the S91 murine malignant melanoma
Wilkinson A note on the use of Stuart's transport medium for the isolation of the Gonococcus
SE8005921L (sv) Nya foreningar med karcinostatisk och immunostimulerande aktivitet samt forfarande for framstellning derav
Tanaka et al. Immunological Study of Pustulosis Palmaris Et Plantaris: Blastoid Transformation of Tonsil and Peripheral Blood Lymphocytes by Stimulation with Human Skin Extract
Ozato et al. Transfer of concanavalin A between responding lymphocytes and syngeneic stimulating cells in cell-mediated mitogenic response
Fridenshteĭn et al. The humoral nature of the colony-stimulating action of bone marrow cells on stromal colony formation in bone marrow cultures
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi
Petrov et al. Nature of a humoral factor of bone marrow stimulating antibody production
Vilcek CELL SUBSTRATES FOR BIOLOGICALS OTHER THAN VACCINES